Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets

Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.